Ankylosing Spondylitis Market, by Drug Type (Nonsteroidal Anti-inflammatory Drugs (NSAIDs), Disease-modifying Anti-rheumatic Drugs (DMARDs), TNF Inhibitors, Corticosteroids, and Others), by Route of Administration (Oral and Parentral), by Distribution Cha

Ankylosing Spondylitis Market, by Drug Type (Nonsteroidal Anti-inflammatory Drugs (NSAIDs), Disease-modifying Anti-rheumatic Drugs (DMARDs), TNF Inhibitors, Corticosteroids, and Others), by Route of Administration (Oral and Parentral), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Ankylosing spondylitis is an inflammation (chronic inflammatory arthritis) that mostly affects the spine. It generally causes stiffness and pain in the back. Over time, movement of the back gradually becomes limited as the bones of the spine become fused. This fusion is called ankylosing. Ankylosing spondylitis can also involve other joints such as the hips, shoulders and sometimes knees. Over time, it can affect the joints between the ribs and spine, restricting the movement of the chest and causing a difficulty in breathing deeply. Symptoms of ankylosing spondylitis include frequent pain and stiffness in buttocks and the lower back, which comes on progressively after a few weeks or months. At first, discomfort may be felt only on one side, or alternate sides. The pain is usually diffuse and dull, rather than localized. Other symptoms in the early stages include loss of appetite, mild fever, and general discomfort. Currently, there is no cure for AS, but there are treatments and drugs available to manage pain and reduce symptoms.
Market Dynamics
The increasing launches of new drugs for ankylosing spondylitis are expected to drive the market growth during the forecast period. For instance, in November 2021, Pfizer’s XELJANZ (tofacitinib) received marketing authorization by the European Commission, in the European Union for the treatment of active ankylosing spondylitis. It received approval for the administration of 5 mg XELJANZ (tofacitinib) twice daily for the treatment of adults with active ankylosing spondylitis (AS) who have not responded adequately to conventional therapy. The approval of XELJANZ for ankylosing spondylitis was based on the data obtained from a Phase 3, multicenter, randomized, double-blind, placebo-controlled study that evaluated the safety and efficacy of XELJANZ (tofacitinib) 5 mg twice daily versus placebo in 269 adult patients with active ankylosing spondylitis.
Key features of the study:
This report provides an in-depth analysis of the global ankylosing spondylitis market, provides market size (US$ Mn), and compound annual growth rate (CAGR%) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global ankylosing spondylitis market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Amgen Inc., AbbVie Inc., Pfizer Inc., Novartis AG, Bristol-Myers Squibb Company, CELGENE CORPORATION, Eli Lilly and Company, Cipla Inc., Emcure Pharmaceuticals, Torrent Pharmaceuticals Ltd., UCB S.A., Suzhou Zelgen Biopharmaceuticals Co., Ltd., HENGRUI USA, and Johnson & Johnson Services, Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global ankylosing spondylitis market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global ankylosing spondylitis market
Detailed Segmentation:
Global Ankylosing Spondylitis Market, By Drug Type:
Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
Disease-modifying Anti-rheumatic Drugs (DMARDs)
TNF Inhibitors
Corticosteroids
Others
Global Ankylosing Spondylitis Market, By Route of Administration:
Oral
Parentral
Global Ankylosing Spondylitis Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Ankylosing Spondylitis Market, By Region:
North America
Drug Type
Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
Disease-modifying Anti-rheumatic Drugs (DMARDs)
TNF Inhibitors
Corticosteroids
Others
Route of Administration
Oral
Parentral
Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
U.S.
Canada
Latin America
Drug Type
Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
Disease-modifying Anti-rheumatic Drugs (DMARDs)
TNF Inhibitors
Corticosteroids
Others
Route of Administration
Oral
Parentral
Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
Brazil
Mexico
Argentina
Rest of Latin America
Europe
Drug Type
Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
Disease-modifying Anti-rheumatic Drugs (DMARDs)
TNF Inhibitors
Corticosteroids
Others
Route of Administration
Oral
Parentral
Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
Drug Type
Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
Disease-modifying Anti-rheumatic Drugs (DMARDs)
TNF Inhibitors
Corticosteroids
Others
Route of Administration
Oral
Parentral
Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
Drug Type
Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
Disease-modifying Anti-rheumatic Drugs (DMARDs)
TNF Inhibitors
Corticosteroids
Others
Route of Administration
Oral
Parentral
Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
GCC
Israel
Rest of Middle East
Africa
Drug Type
Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
Disease-modifying Anti-rheumatic Drugs (DMARDs)
TNF Inhibitors
Corticosteroids
Others
Route of Administration
Oral
Parentral
Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region/Country
South Africa
Central Africa
North Africa
Company Profiles
Amgen Inc.
Company Highlights
Products Portfolio
Key Highlights
Financial Performance
Strategies
AbbVie Inc.
Pfizer Inc.
Novartis AG
Bristol-Myers Squibb Company
CELGENE CORPORATION
Eli Lilly and Company
Cipla Inc.
Emcure Pharmaceuticals
Torrent Pharmaceuticals Ltd.
UCB S.A.
Suzhou Zelgen Biopharmaceuticals Co., Ltd.
HENGRUI USA
Johnson & Johnson Services, Inc.
“*” marked represents similar segmentation in other categories in the respective section.